Geri Dön

Mesane tümörlerinde p53, Ki67, bcl-2 ve MDM-2 ekspresyonu ve klinikopatolojik parametreler ile ilişkisi

Expressions of p53, Ki67, bcl2 and MDM-2 in bladder tumors and their relationship to the clinicopathologic parameters

  1. Tez No: 130000
  2. Yazar: İPEK IŞIK GÖNÜL
  3. Danışmanlar: PROF. DR. AYŞE DURSUN
  4. Tez Türü: Tıpta Uzmanlık
  5. Konular: Patoloji, Pathology
  6. Anahtar Kelimeler: Belirtilmemiş.
  7. Yıl: 2003
  8. Dil: Türkçe
  9. Üniversite: Gazi Üniversitesi
  10. Enstitü: Tıp Fakültesi
  11. Ana Bilim Dalı: Patoloji Ana Bilim Dalı
  12. Bilim Dalı: Belirtilmemiş.
  13. Sayfa Sayısı: 82

Özet

64 SUMMARY The two most important parameters that determines the prognosis and treatment in transitional cell carcinomas, which are the most commonly seen tumours of the bladder, are grading and staging. Recently, two new classification systems (WHO/ISUP 1998 and WHO/ISUP 1999) for grading of urothelial neoplasms have been published and the most widely grading system throughout the world, WHO 1 973 grading system is being critised. The present study examined 72 patients with transitional cell carcinomas that were graded according to the WHO 1973, WHO/ISUP 1998 and WHO/ISUP 1999 consensus classifications. The relationships between tumour grades in three different systems and stage, angiolymphatic invasion, mitotic index, Kİ67, p53, MDM-2 and bcl-2 expressions together with their prognostic significance were investigated. We found a significant correlation between pathologic stage, mitotic index, angiolymphatic invasion and tumour grades according to the three different systems (p0.05). Kİ67 and p53 expressions correlated with tumour grades in WHO 1973 grading system (p0.05). As a result. WHO 1973 grading system is still the international standart for the classification and grading of urothelial neoplasms. It can distinguish the tumours in different prognostic groups which show a significant difference in Kİ67 and p53 expressions. WHO/ISUP 1998 and WHO/ISUP 1999 grading systems are not overtly superior to WHO 1973 system. But if“urothelial neoplasm of low malignant potential”category of the WHO/ISUP 1998 and 1999 grading systems is distinguished from gradel tumours in WHO 1 973 system, more precise prognostic information can be obtained. Proliferative activity of the tumors determined by Kİ67 expression and p53 expression could be used in the determination of the prognosis when used together with grading systems and staging.

Özet (Çeviri)

64 SUMMARY The two most important parameters that determines the prognosis and treatment in transitional cell carcinomas, which are the most commonly seen tumours of the bladder, are grading and staging. Recently, two new classification systems (WHO/ISUP 1998 and WHO/ISUP 1999) for grading of urothelial neoplasms have been published and the most widely grading system throughout the world, WHO 1 973 grading system is being critised. The present study examined 72 patients with transitional cell carcinomas that were graded according to the WHO 1973, WHO/ISUP 1998 and WHO/ISUP 1999 consensus classifications. The relationships between tumour grades in three different systems and stage, angiolymphatic invasion, mitotic index, Kİ67, p53, MDM-2 and bcl-2 expressions together with their prognostic significance were investigated. We found a significant correlation between pathologic stage, mitotic index, angiolymphatic invasion and tumour grades according to the three different systems (p0.05). Kİ67 and p53 expressions correlated with tumour grades in WHO 1973 grading system (p0.05). As a result. WHO 1973 grading system is still the international standart for the classification and grading of urothelial neoplasms. It can distinguish the tumours in different prognostic groups which show a significant difference in Kİ67 and p53 expressions. WHO/ISUP 1998 and WHO/ISUP 1999 grading systems are not overtly superior to WHO 1973 system. But if“urothelial neoplasm of low malignant potential”category of the WHO/ISUP 1998 and 1999 grading systems is distinguished from gradel tumours in WHO 1 973 system, more precise prognostic information can be obtained. Proliferative activity of the tumors determined by Kİ67 expression and p53 expression could be used in the determination of the prognosis when used together with grading systems and staging.

Benzer Tezler

  1. Yüzeyel mesane tümörlerinde P16, Kİ-67, Bcl-2, P53, CK20 immünekspresyonlarının nüks ile ilişkisi

    Başlık çevirisi yok

    ÖZBEN YALÇIN

    Tıpta Uzmanlık

    Türkçe

    Türkçe

    2010

    PatolojiMarmara Üniversitesi

    Patoloji Ana Bilim Dalı

    DOÇ. DR. FUNDA TANAY EREN

  2. Mesanenin transizyonel hücreli karsinomlarında Ki-67, P53, BcL-2, Bax ekspresyonu ile histolojik grade, patolojik evre ve prognoz arasındaki ilişki

    The relationship between Ki-67, P53, BcL-2, Bax expression with histologic grade, pathologic stage and prognosis in bladder transtional cell carcinomas

    NİLAY ŞEN

    Tıpta Uzmanlık

    Türkçe

    Türkçe

    2003

    PatolojiPamukkale Üniversitesi

    Patoloji Ana Bilim Dalı

    PROF. DR. S. ENDER DÜZCAN

  3. Mesanenin ürotelyal tümörlerinde p53, maspin, ki67 immünhistokimyasal ekspresyonu

    Immunhistochemical expression of p53, maspin, ki67 in urothelial tumors of the bladder

    GÜLCAN YAVUZ

    Tıpta Uzmanlık

    Türkçe

    Türkçe

    2011

    PatolojiSüleyman Demirel Üniversitesi

    Tıbbi Patoloji Ana Bilim Dalı

    DOÇ. DR. SEMA BİRCAN

  4. Mesanenin yüzeyel üretelyal hücreli karsinomlarında p53 ve Ki-67 ekspresyonlarının prognoz ile ilişkisi

    Başlık çevirisi yok

    NURCAN KILIÇLI ÇAMUR

    Tıpta Uzmanlık

    Türkçe

    Türkçe

    1999

    Onkolojiİstanbul Üniversitesi

    Patoloji Ana Bilim Dalı

  5. Orta ve yüksek riskli mesane tümörlerinde prognozu belirlemede doku markerlerinin yeri

    Role of tissue markers on predicting prognosis of intermediate and high risk non muscle invasive bladder cancer

    ABULFAZ ABBASLI

    Tıpta Uzmanlık

    Türkçe

    Türkçe

    2015

    Ürolojiİstanbul Üniversitesi

    Üroloji Ana Bilim Dalı

    PROF. DR. NUR AHMET ERÖZENCİ